### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

# **FORM 8-K**

**CURRENT REPORT** 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (date of earliest event reported): May 9, 2023

## EHEALTH, INC.

(Exact Name of Registrant as Specified in its Charter) 001-33071

(Commission File Number)

56-2357876 (I.R.S. Employer Identification No.)

Delaware (State or other jurisdiction of incorporation)

2625 AUGUSTINE DRIVE, SUITE 150

SANTA CLARA, CA 95054 (Address of principal executive offices) (Zip Code)

(650) 210-3150

(Registrant's telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	EHTH	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  $\Box$ 

### Item 2.02 Results of Operations and Financial Condition.

On May 9, 2023, eHealth, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2023 and its financial condition as of March 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On May 9, 2023, the Company posted supplemental investor material on its investor relations webpage at http://ir.ehealthinsurance.com. The Company intends to use its investor relations webpage as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. A copy of the supplemental investor materials is also furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in Item 2.02 of this Current Report on Form 8-K and the exhibits attached hereto are intended to be "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Except as shall be expressly set forth by specific reference in such filing, the information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits	
Exhibit No.	<b>Description</b>
99.1	Press Release of eHealth, Inc. dated May 9, 2023 (eHealth, Inc. Announces First Quarter 2023 Results)
99.2	Financial Results Conference Call Slides of eHealth, Inc. dated May 9, 2023
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 9, 2023

eHealth, Inc. /s/ John Stelben

John Stelben Chief Financial Officer (Principal Financial Officer)



### eHealth, Inc. Announces First Quarter 2023 Results

Strong first quarter performance reflects positive impact of ongoing transformation plan

Continued positive trends in unit economics drive YoY Q1 profitability improvement

### \$12.9M improvement in net loss and \$12.2M improvement in adjusted EBITDA YoY

29% increase in cash flow from operations YoY

SANTA CLARA, California — May 9, 2023 — eHealth, Inc. (Nasdaq: EHTH), a leading private online health insurance marketplace, today announced its financial results for the first quarter ended March 31, 2023.

### **CEO Comments**

"We delivered strong first quarter performance, reflecting the positive impact of the transformation plan that we started to implement in Q2 of 2022. We entered the first quarter of this year on a significantly improved cost foundation compared to the first quarter of last year while continuing to enhance our telesales conversions, member economics and enrollment quality. eHealth observed another 50% year-over-year decrease in its CTM rates from Q1 2022 to Q1 2023 based on data available to-date. Many of our key carrier partners have recognized this important service improvement. Based on our encouraging first quarter results, we are reaffirming the guidance ranges we gave on last quarter's earnings call for 2023. Our year-to-date performance has put us in a strong position as we continue to execute on our strategic and operational goals. We look forward to sharing more information about our business, strategy, and longer-term financial goals at our investor day, on May 18th." – Fran Soistman, Chief Executive Officer

### Results Overview

- Q1 2023 revenue decreased 30% to \$73.7 million compared to \$105.3 million in Q1 2022 demonstrating eHealth's focus on profitable growth versus top-line growth at any cost.
- Q1 2023 total operating costs and expenses decreased 33% to \$96.6 million compared to \$145.0 million in Q1 2022 driven by significant fixed and variable cost reduction as
  a result of our cost transformation efforts.
- Q1 2023 net loss of \$19.9 million improved \$12.9 million compared to Q1 2022.
- Q1 2023 Adjusted EBITDA<sup>(1)</sup> of \$(12.7) million improved \$12.2 million compared to Q1 2022 on a lower revenue base.
- Q1 2023 cash flow from operations of \$60.8 million compared to \$47.1 million in Q1 2022, a 29% increase.
- \$202.7 million in cash, cash equivalents and marketable securities as of March 31, 2023.
- Unit economics continue to improve on a year-over-year basis with total acquisition costs per MA-equivalent approved member down 22% compared to Q1 2022.
  - Customer care and enrollment expense per MA-equivalent approved member down 15% year-over-year.
  - Variable marketing cost per MA-equivalent approved member down 27% year-over-year.
- Q1 2023 telephonic conversion rates continued to improve on a year-over-year basis, increasing 21% compared to Q1 2022.

Note: See tables at the end of this press release for a reconciliation of our GAAP financial measures to our non-GAAP financial measures for the relevant periods and footnote (1) on page 12 at the end of this press release for definitions of our non-GAAP financial measures.

### 2023 Guidance

Based on information available as of May 9, 2023, we are reaffirming our previously issued guidance for the full year ending December 31, 2023. These expectations are forwardlooking statements and we assume no obligation to update these statements. Actual results may be materially different and are affected by the risk factors and uncertainties identified in this press release and in eHealth's annual and quarterly reports filed with the Securities and Exchange Commission.

The following guidance is for the full year ending December 31, 2023:

- Total revenue is expected to be in the range of \$420 million to \$440 million.
- GAAP net loss is expected to be in the range of \$55 million to \$35 million.
- Adjusted EBITDA<sup>(1)</sup> is expected to be in the range of \$(15) million to \$5 million.
- Operating cash flow is expected to be in the range of \$(30) million to \$(15) million.

### Webcast and Conference Call Information

A webcast and conference call will be held today, Tuesday, May 9, 2023 at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time. Individuals interested in listening to the conference call may do so by dialing (888) 259-6580. The participant passcode is 22387816. The live and archived webcast of the call will also be available on eHealth's website at <a href="http://www.ehealthinsurance.com">http://www.ehealthinsurance.com</a> under the Investor Relations section.

### About eHealth, Inc.

For over 25 years, eHealth, Inc. (Nasdaq: EHTH) has expertly guided American consumers with innovative technology and licensed advisor support to help them find health insurance and related options. Through its proprietary health insurance marketplace at <u>eHealth.com</u>, eHealth has connected more than eight million members with quality, affordable coverage. eHealth offers Medicare Advantage, Medicare Supplement, Medicare Part D, individual, family, small business, and ancillary plans from approximately 200 health insurance companies nationwide. For more information about eHealth, please visit us at <u>eHealth.com</u>, or follow us on <u>LinkedIn</u>, <u>Facebook</u>, <u>Instagram</u>, and <u>Twitter</u>.

### Forward-Looking Statements

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. These include statements regarding our expectations for enrollment growth and quality, our expectations regarding our financial performance, our expectations regarding telesales conversion rates, our estimates regarding total membership, Medicare, individual and family plan, ancillary products, and small business memberships, our estimates regarding constrained lifetime values of commissions per approved member by product category, our estimates regarding costs per approved member, and our 2023 annual guidance for total revenue, GAAP net loss, adjusted EBITDA and operating cash flow.

These forward-looking statements are inherently subject to various risks and uncertainties that could cause actual results to differ materially from the statements made. In particular, we are required by Accounting Standards Codification 606 — Revenue from Contracts with Customers to make numerous assumptions that are based on historical trends and our management's judgment. These assumptions may change over time and have a material impact on our revenue recognition, guidance, and results of operations. Please review the assumptions stated in this press release carefully.

The risks and uncertainties that could cause our results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, our ability to retain existing members and enroll new members during the annual healthcare open enrollment period, the Medicare Advantage open enrollment period and other special enrollment periods; changes in laws, regulations and guidelines, including in connection with healthcare reform or with respect to the marketing and sale of Medicare plans; competition, including competition from government-run health insurance exchanges and other sources; the seasonality of our business and the fluctuation of our operating results; our ability to accurately estimate membership, lifetime value of commissions and commissions receivable; changes in product offerings among carriers on our ecommerce platform and changes in our estimated conversion rate of an approved member to a paying member and the resulting impact of each on our commission revenue; the concentration of our revenue with a small number of health insurance excirces; our ability to execute on our growth strategy and other business initiatives; changes in our management and key employees; our ability to hire, train, retain and ensure the productivity of

licensed health insurance agents and other employees; exposure to security risks and our ability to safeguard the security and privacy of confidential data; our relationships with health insurance carriers and our reliance on a small number of health insurance carriers; the success of our carrier advertising and sponsorship program; our success in marketing and selling health insurance plans and our unit cost of acquisition; our ability to effectively manage our operations as our business evolves and execute on our transformation plan and other strategic initiatives; the need for health insurance carrier and regulatory approvals in connection with the marketing of Medicare-related insurance products; changes in the market for private health insurance; consumer satisfaction of our service and actions we take to improve the quality of enrollments; changes in member conversion rates; changes in commission rates; our ability to sell qualified health insurance; plans to subsidy-eligible individuals and to enroll subsidy-eligible individuals through government-run health insurance exchange; our ability to maintain and enhance our brand identity; our ability to desired benefits from investments in our business, including membership growth and retention initiatives; reliance on marketing partners; the impact of our direct-to-consumer mail, email, social media, telephone and television marketing efforts; timing of receipt and accuracy of commission reports; payment practices of health insurance carriers; dependence on our operations in China; the restrictions in our investment agreement with convertible preferred stock investors; our ability to arise additional capital; compliance with insurance, privacy and other laws and regulations; the restrictions and other extreme events; general economic conditions, including any new systems we may implement; public health crises, pandemics, natural disasters, changing climate conditions and other extreme events; general economic conditions, including inflation, recession, financ

All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

### **Investor Relations Contact**

Kate Sidorovich, CFA Senior Vice President, Investor Relations & Strategy 2625 Augustine Drive, Suite 150 Santa Clara, CA, 95054 kate.sidorovich@ehealth.com http://ir.ehealthinsurance.com

### EHEALTH, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, unaudited)

	March 31, 2023		December 31, 2022		
Assets					
Current assets:					
Cash and cash equivalents	\$	180,633	\$	144,401	
Short-term marketable securities		22,059		_	
Accounts receivable		1,027		2,633	
Contract assets – commissions receivable – current		205,679		242,749	
Prepaid expenses and other current assets		11,266		11,301	
Total current assets		420,664		401,084	
Contract assets – commissions receivable – non-current		596,354		641,555	
Property and equipment, net		4,994		5,501	
Operating lease right-of-use assets		25,381		26,516	
Restricted cash		3,239		3,239	
Other assets		32,402		34,716	
Total assets	\$	1,083,034	\$	1,112,611	
Liabilities, convertible preferred stack and stackbalders' amity					
Liabilities, convertible preferred stock and stockholders' equity Current liabilities:					
Accounts payable	\$	5.273	ŕ	6.732	
Accounts payable Accrued compensation and benefits	φ	27,884	φ	20.690	
Accrued compensation and benefits		8.751		20,090	
Lease liabilities – current		6,628		6,486	
Other current liabilities		2,931		2.887	
Total current liabilities		51.467		60.565	
		66,508		66,129	
Long-term debt Deferred income taxes – non-current		28,748		32,359	
Lease liabilities – non-current		32,549		34,187	
Other non-current liabilities		4,400		5.132	
Total liabilities	. <u></u>	183.672		198.372	
		183,672 271,454		/ -	
Convertible preferred stock		271,454		263,284	
Stockholders' equity:		40		40	
Common stock		40 782.065			
Additional paid-in capital		- ,		777,187	
Treasury stock, at cost		(199,998)		(199,998) 73,799	
Retained earnings		45,751		-,	
Accumulated other comprehensive income (loss)		50		(73)	
Total stockholders' equity		627,908	-	650,955	
Total liabilities, convertible preferred stock, and stockholders' equity	\$	1,083,034	\$	1,112,611	

### EHEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts, unaudited)

		Three Months Ended March 31,			
		2023		2022	% Change
Revenue:					
Commission	\$	68,003	\$	93,850	(28)%
Other		5,720		11,400	(50)%
Total revenue		73,723		105,250	(30)%
Operating costs and expenses <sup>(a)</sup> :					
Cost of revenue		215		(127)	269 %
Marketing and advertising		32,899		58,454	(44)%
Customer care and enrollment		26,957		42,164	(36)%
Technology and content		15,544		19,663	(21)%
General and administrative		21,002		19,987	5 %
Impairment, restructuring and other charges		_		4,823	(100)%
Total operating costs and expenses		96,617		144,964	(33)%
Loss from operations		(22,894)		(39,714)	42 %
Other expense, net		(592)		(1,021)	42 %
Loss before income taxes		(23,486)		(40,735)	42 %
Benefit from income taxes		(3,608)		(7,993)	
Net loss		(19,878)		(32,742)	39 %
Paid-in-kind dividends for preferred stock		(5,101)		(4,717)	
Change in preferred stock redemption value		(3,069)		(2,501)	
Net loss attributable to common stockholders	\$	(28,048)	\$	(39,960)	30 %
Net loss per share attributable to common stockholders:					
Basic and diluted	\$	(1.01)	\$	(1.46)	31 %
Weighted-average number of shares used in per share:	÷	(	•	(	
Basic and diluted		27,648		27,278	1 %
(a) Includes stock-based compensation expense as follows:					
Marketing and advertising	\$	455	\$	313	
Customer care and enrollment		605		454	
Technology and content		905		1,850	
General and administrative		3,029		2,668	
Total stock-based compensation expense	\$	4,994	\$	5,285	(6)%
Non-GAAP Results <sup>(1)</sup> :					
Adjusted EBITDA	\$	(12,655)	\$	(24,828)	49 %
Adjusted EBITDA margin	<b></b>	(12,000)	*	(24)%	(27)%

5

Note: See accompanying footnotes on page 12.

### EHEALTH, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands, unaudited)

Depressing activities:         2023         2022           Net loss         \$ (19,876)         \$ (19,876)         \$ (32,742)           Adjustments to reconcile net loss to net cash used in operating activities:         656         946           Depreciation and anoritzation         4,589         3,332           Stock-based compensation expense         4,994         5,285           Deferred income taxes         (3,611)         (8,032)           Other non-cash thems         61         2155           Accounts receivable         1,005         3,773           Contract assets - commissions receivable         1,005         3,773           Contract assets - commissions receivable         1,005         3,773           Accounts payable         (1425)         12,2418           Accound marketing expenses         (125)         12,418           Accound marketing expenses         (1439)         (5,525)           Accrued expenses and other assets         (7)193         2,042           Accrued expenses and other assets         (67)         (55)           Defered revenue         (304)         4,829           Defered expenses         (67)         (55)           Accrued expenses and other assets         (67)         (55)			Months Ended /arch 31,
Net los         \$         (19,878)         \$         (32,742)           Adjustments to reconcile net loss on et cash used in operating activities:         ************************************		2023	2022
Adjustments to reconcile net loss to net cash used in operating activities:       656       946         Depreciation and amoritzation       656       946         Amoritzation of internally developed software       4,589       3,532         Stock-based compensation expense       4,994       5,285         Deferred income taxes       61       215         Changes in operating assets and liabilities:       61       215         Accounts receivable       1,605       3,773         Contract assets - commissions receivable       1,605       3,773         Contract assets - commissions receivable       1,125       1,2,418         Accounts payable       (1,453)       6,2,422         Accrued compensation and benefits       7,1133       2,042         Accrued compensation and benefits       61,032       1,16,343         Deferend revenue       (372)       (223)         Accrued compensation and benefits       60,803       47,112         Investing activities:       (2,164)       (4,205)         Investing activities:       (2,164)       (4,205)         Capitalized internal-use software and website development costs       (2,164)       (4,205)         Purchases of property and equipment and other assets       (677)       (55)	Operating activities:		
Depreciation and anotization         656         946           Amortization of internally developed software         4,589         3,832           Stock-based compensation expense         4,994         6,285           Deferred income taxes         (3,611)         (8,032)           Other non-cash items         61         215           Accounts receivable         1,605         3,773           Contract assets - commissions receivable         82,507         77,142           Prepaid expenses and other assets         (125)         12,418           Accounds receivable         (1493)         (5,525)           Accrued compensation and benefits         (304)         4,629           Accrued compensation and benefits         (304)         4,629           Accrued taxeting expenses         (15,019)         (16,648)           Deferred revenue         (304)         4,629           Accrued expenses and other liabilities         (204)         4,629           Purchases of property and equipment and other assets         (21,614)         (4,205)           Purchases of property and equipment and other assets         (21,614)         (24,200)           Proceeds from recervities         —         3,4319           Net cash provided by (used in) investing activities         <	Net loss	\$ (19,87	'8) \$ (32,742)
Amoutzation of internally developed software         4.589         3.832           Stock-based compensation expense         4.994         5.285           Deferred income taxes         (3.611)         (8.032)           Other non-cash items         61         215           Accounts receivable         1.605         3.773           Contract assets - commissions receivable         82.507         77.142           Prepaid expenses and other assets         (125)         12.418           Accounts payable         (1.493)         (5.525)           Accrued marketing expenses         (15.019)         (16.848)           Deferred revenue         (372)         (223)           Accrued expenses and other liabilities         (304)         4.829           Investing activities:         (204)         4.220           Captalized internal-use software and website development costs         (2.164)         (4.205)           Purchases of property and equipment and other assets         (2.200)         (3.338)           Proceeds from redemption and maturities of marketable securities         (2.200)         (3.338)           Proceeds from redemption and maturities of marketable securities         (2.200)         (3.338)           Proceeds from redemption and maturities of marketable securities         (4.205)	Adjustments to reconcile net loss to net cash used in operating activities:		
Stock-based compensation expense         4,994         5,285           Deferred income taxes         (3,611)         (6,302)           Other non-cash items         61         215           Changes in operating assets and liabilities:	Depreciation and amortization	65	6 946
Deferred income taxes         (3.611)         (8.032)           Other non-cash items         61         215           Changes in operating assets and liabilities:         61         215           Accounts receivable         1.605         3.773           Contrat assets - commissions receivable         82.507         77.142           Prepaid expenses and other assets         (125)         12.418           Accounts payable         (1,493)         (5.525)           Accrued compensation and benefits         7,193         2.042           Accrued compensation and benefits         (361)         (4.849)           Deferred revenue         (304)         4.829           Accrued marketing expenses and other liabilities         (304)         4.829           Net cash provided by operating activities         (67)         (55)           Investing activities         (2164)         (4.205)           Purchases of property and equipment and other assets         (67)         (55)           Purchases of property and equipment and other assets         (2164)         (4.205)           Purchases of property and equipment and other assets         (24,240)         (24,240)           Purchases of property and equipment and other assets         (24,240)         (24,210)           Proc	Amortization of internally developed software	4,58	39 3,832
Other non-cash items         61         215           Changes in operating assets and liabilities:	Stock-based compensation expense	4,99	94 5,285
Changes in operating assets and liabilities:     1,605     3,773       Accounts receivable     1,605     3,773       Contract assets - commissions receivable     1,605     3,773       Contract assets - commissions receivable     1,250     12,418       Accounts payable     (1,493)     (5,525)       Accrued compensation and benefits     7,193     2,042       Accrued marketing expenses     (15,019)     (16,848)       Deferred revenue     (372)     (223)       Accrued expenses and other liabilities     (304)     4,829       Net cash provided by operating activities     60,803     47,112       Investing activities     (67)     (55)       Purchases of property and equipment and other assets     (2,164)     (4,205)       Purchases of marketable securities     (2,200)     (3,38)       Proceeds from redemption and maturities of marketable securities     -     34,319       Putrobase of store set of comonn stock options and employee stock purchases     -     1,054       Repurchase of store s to astisfy employee tax withholding obligations     (428)     (508)       Proceeds from debt financing     -     64,862       Provided by (used in financing activities     -     1,054       Repurchase of stores to satisfy employee tax withholding obligations     (428)     (508)    <	Deferred income taxes	(3,6*	(8,032)
Accounts receivable         1,605         3,773           Contract assets - commissions receivable         82,507         77,142           Prepaid expenses and other assets         (125)         12,418           Accounts payable         (1,493)         (6,525)           Accrued compensation and benefits         7,193         2,042           Accrued marketing expenses         (15,019)         (16,848)           Deferred revenue         (372)         (223)           Accrued expenses and other liabilities         (304)         4,829           Net cash provided by operating activities         (60,803)         47,112           Investing activities:         (67)         (55)           Capitalized internal-use software and website development costs         (2,164)         (4,205)           Purchases of property and equipment and other assets         (67)         (55)           Purchases of marketable securities         (2,164)         (24,205)           Purchases of marketable securities         (2,164)         (24,205)           Purchases of marketable securities         (67)         (55)           Purchases of marketable securities         (2,164)         (24,205)           Purchases of marketable securities         (2,164)         (24,205)           Purchases	Other non-cash items		j1 215
Contract assets - commissions receivable         82,507         77,142           Prepaid expenses and other assets         (125)         12,418           Accounds payable         (1,43)         (55,52)           Accrued compensation and benefits         7,193         2,042           Accrued marketing expenses         (15,019)         (16,848)           Deferred revenue         (372)         (223)           Accrued expenses and other liabilities         (304)         4.829           Net cash provided by operating activities         60,803         47,112           Investing activities:         (21,64)         (4,205)           Purchases of property and equipment and other assets         (67)         (65)           Purchases of marketable securities         -         34,318           Proceeds from redemption and maturities of marketable securities         -         34,319           Net cash provided by (used in) investing activities         -         64,862           Net proceeds from redemption and explores toke purchases         -         10,54           Principal parments in connection with leases         -         10,54           Net proceeds from exercise of common stock options and employee stock purchases         -         10,54           Repurchase of shares to satisfy employee tax withholding	Changes in operating assets and liabilities:		
Prepaid expenses and other assets(125)12,418Accounts payable(1,493)(5,525)Accrued compensation and benefits7,1932,042Accrued marketing expenses(16,519)(16,848)Deferred revenue(372)(223)Accrued expenses and other liabilities(304)4,829Net cash provided by operating activities60,80347,112Investing activities(2,164)(4,205)Purchases of property and equipment and other assets(2,164)(4,205)Purchases of marketable securities(22,009)(3,388)Proceeds from redemption and maturities of marketable securities-34,319Net cash provided by (used in) investing activities-64,862Purchases of starketable securities-10,648Proceeds from exercise of common stock options and employee stock purchases-10,658Net proceeds from exercise of common stock options and employee stock purchases-10,658Principal payments in connection with leases(11)(35)Net cash provided by (used in) financing activities-10,654Principal payments in connection with leases-10,654Net proceeds from exercise of common stock options and employee stock purchases-10,656Net proceeds in principal payments in connection with leases-10,654Net cash provided by (used in) financing activities(439)65,373Effect of exchange rate changes on cash, cash equivalents and restricted cash36,6232138,637<	Accounts receivable	1,60	)5 3,773
Accounts payable         (1,493)         (5,525)           Accrued compensation and benefits         7,193         2,042           Accrued marketing expenses         (15,019)         (16,848)           Deferred revenue         (372)         (223)           Accrued expenses and other liabilities         (304)         4,829           Net cash provided by operating activities         60,803         47,112           Investing activities         60,803         47,112           Capitalized internal-use software and website development costs         (2,164)         (4,205)           Purchases of marketable securities         (22,009)         (3,338)           Proceeds from redemption and maturities of marketable securities         (24,240)         (26,121)           Financing activities:         (24,240)         26,121           Financing activities:         (428)         (508)           Net proceeds from exercise of common stock options and employee stock purchases         —         1,054           Repurchases of shares to satisfy employee tax withholding obligations         (428)         (508)           Net proceeds from exercise of common stock options and enstricted cash         (11)         (355)           Net proceeds from exercise of shares to satisfy employee tax withholding obligations         (428)         (508)	Contract assets – commissions receivable	82,50	77,142
Accrued compensation and benefits7,1932,042Accrued marketing expenses(15,019)(16,848)Deferred revenue(372)(223)Accrued expenses and other liabilities(304)4,829Net cash provided by operating activities60,80347,112Investing activities:(2,164)(4,205)Capitalized internal-use software and website development costs(67)(55)Purchases of property and equipment and other assets(67)(55)Purchases of marketable securities-34,319Net cash provided by (used in) investing activities(24,240)26,121Financing activities:-34,319Net proceeds from redemption and maturities of marketable securities-64,862Net proceeds from debt financing-64,862Net proceeds from exercise of common stock options and employee stock purchases(11)(35)Principal payments in connection with leases(11)(35)Net cash provided by (used in) financing activities(439)66,373Effect of exchange rate changes on cash, cash equivalents and restricted cash10831Net increase in cash, cash equivalents and restricted cash36,832138,637Cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash36,232138,637	Prepaid expenses and other assets	(12	25) 12,418
Accrued marketing expenses(15,019)(16,848)Deferred revenue(372)(223)Accrued expenses and other liabilities(304)4,829Net cash provided by operating activities60,80347,112Investing activities:(2,164)(4,205)Purchases of property and equipment and other assets(67)(55)Purchases of marketable securities(22,009)(3,938)Proceeds from redemption and maturities of marketable securities-34,319Net cash provided by (used in) investing activities(24,240)26,121Net proceeds from redemption and sturities of common stock options and employee stock purchases-64,862Net proceeds from exercise of common stock options and employee stock purchases-1,054Repurchase of starts of purchases(11)(35)Net cash provided by (used in) financing activities(11)(35)Net ash provided by (used in) financing activities-36,373Effect of exchange rate changes on cash, cash equivalents and restricted cash10831Isticate ash provided by (used in) financing activities-36,373Effect of exchange rate changes on cash, cash equivalents and restricted cash36,37336,373Cash, cash equivalents and restricted cash36,37336,373Cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and re	Accounts payable	(1,49	3) (5,525)
Deferred revenue(372)(223)Accrued expenses and other liabilities(304)4.829Net cash provided by operating activities60,80347,112Investing activities:(2,164)(4,205)Purchases of property and equipment and other assets(67)(55)Purchases of property and equipment and other assets(22,009)(3,398)Proceeds from redemption and maturities of marketable securities(24,240)26,121Financing activities:(24,240)26,121Financing activities:-1,054Net proceeds from exercise of common stock options and employee stock purchases(428)(508)Principal payments in connection with leases(11)(35)Repurchase of shares to satisfy employee tax withholding obligations(439)65,373Effect of exchange rate changes on cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash36,252138,637	Accrued compensation and benefits	7,19	3 2,042
Accrued expenses and other liabilities(304)(4.829Net cash provided by operating activities60,80347,112Investing activities:60,80347,112Capitalized internal-use software and website development costs(2,164)(4,205)Purchases of property and equipment and other assets(67)(55)Purchases of marketable securities(22,009)(3,938)Proceeds from redemption and maturities of marketable securities(24,240)26,121Financing activities:(24,240)26,121Net cash provided by (used in) investing activities(24,240)26,121Financing activities:(11)(35)Net proceeds from debt financing(428)(508)Principal payments in connection with leases(11)(35)Net cash provided by (used in) financing activities(439)65,373Principal payments in connection with leases(108)31Net increase in cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash36,5165147,640	Accrued marketing expenses	(15,01	9) (16,848)
Net cash provided by operating activities60,80347,112Investing activities:Capitalized internal-use software and website development costs(2,164)(4,205)Purchases of property and equipment and other assets(67)(55)Purchases of marketable securities(22,009)(3,938)Proceeds from redemption and maturities of marketable securities-34,319Net cash provided by (used in) investing activities(24,240)26,121Financing activities:1,054Net proceeds from exercise of common stock options and employee stock purchases-1,054Repurchase of shares to satisfy employee tax withholding obligations(428)(508)Principal payments in connection with leases(11)(35)Net cash provided by (used in) financing activities(439)65,373Effect of exchange rate changes on cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash51,655147,640	Deferred revenue	(37	(223)
Investing activities:Capitalized internal-use software and website development costs(2,164)(4,205)Purchases of property and equipment and other assets(67)(55)Purchases of marketable securities(22,009)(3,938)Proceeds from redemption and maturities of marketable securities-34,319Net cash provided by (used in) investing activities(24,240)26,121Financing activities:-64,862Net proceeds from debt financing-1,054Repurchase of shares to satisfy employee tax withholding obligations(428)(508)Principal payments in connection with leases(11)(35)Net cash provided by (used in) financing activities(439)65,373Net cash provided by (used in) financing activities(439)65,373Principal payments in connection with leases10831Net increase in cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash at beginning of period147,64085,165	Accrued expenses and other liabilities	(30	4,829
Capitalized internal-use software and website development costs(2,164)(4,205)Purchases of property and equipment and other assets(67)(55)Purchases of marketable securities(22,009)(3,938)Proceeds from redemption and maturities of marketable securities-34,319Net cash provided by (used in) investing activities(24,240)(24,240)Financing activities:-64,862Net proceeds from exercise of common stock options and employee stock purchases-1,054Repurchase of shares to satisfy employee tax withholding obligations(428)(508)Principal payments in connection with leases(11)(35)Net cash provided by (used in) financing activities(439)65,373Effect of exchange rate changes on cash, cash equivalents and restricted cash10831Net increase in cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash at beginning of period147,64085,165	Net cash provided by operating activities	60,80	47,112
Purchases of property and equipment and other assets(67)(55)Purchases of marketable securities(22,009)(3,938)Proceeds from redemption and maturities of marketable securities-34,319Net cash provided by (used in) investing activities(24,240)26,121Financing activities:-64,862Net proceeds from exercise of common stock options and employee stock purchases-1,054Repurchase of shares to satisfy employee tax withholding obligations(428)(508)Principal payments in connection with leases(11)(35)Net cash provided by (used in) financing activities65,37331Net procees in cash, cash equivalents and restricted cash10831Net increase in cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash at beginning of period147,64085,165	Investing activities:		
Purchases of marketable securities(22,009)(3,938)Proceeds from redemption and maturities of marketable securities—34,319Net cash provided by (used in) investing activities(24,240)26,121Financing activities:(24,240)26,121Net proceeds from debt financing—64,862Net proceeds from exercise of common stock options and employee stock purchases—1,054Repurchase of shares to satisfy employee tax withholding obligations(428)(508)Principal payments in connection with leases(11)(35)Net cash provided by (used in) financing activities(439)65,373Effect of exchange rate changes on cash, cash equivalents and restricted cash10831Net increase in cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash147,64085,165	Capitalized internal-use software and website development costs	(2,16	(4,205)
Proceeds from redemption and maturities of marketable securities-34,319Net cash provided by (used in) investing activities(24,240)26,121Financing activities:-64,862Net proceeds from debt financing-64,862Net proceeds from exercise of common stock options and employee stock purchases-1,054Repurchase of shares to satisfy employee tax withholding obligations(428)(508)Principal payments in connection with leases(11)(35)Net cash provided by (used in) financing activities(439)65,373Effect of exchange rate changes on cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash36,232138,637	Purchases of property and equipment and other assets	(6	(55)
Net cash provided by (used in) investing activities(24,240)26,121Financing activities: Net proceeds from debt financing—64,862Net proceeds from exercise of common stock options and employee stock purchases—1,054Repurchase of shares to satisfy employee tax withholding obligations(428)(508)Principal payments in connection with leases(11)(35)Ket cash provided by (used in) financing activities(439)65,373Effect of exchange rate changes on cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash36,232138,637	Purchases of marketable securities	(22,00	(3,938)
Financing activities:       —       64,862         Net proceeds from debt financing       —       64,862         Net proceeds from exercise of common stock options and employee stock purchases       —       1,054         Repurchase of shares to satisfy employee tax withholding obligations       (428)       (508)         Principal payments in connection with leases       (11)       (35)         Net cash provided by (used in) financing activities       (439)       65,373         Effect of exchange rate changes on cash, cash equivalents and restricted cash       108       311         Net increase in cash, cash equivalents and restricted cash       36,232       138,637         Cash, cash equivalents and restricted cash at beginning of period       147,640       85,165	Proceeds from redemption and maturities of marketable securities		— 34,319
Net proceeds from debt financing64,862Net proceeds from exercise of common stock options and employee stock purchases1,054Repurchase of shares to satisfy employee tax withholding obligations(428)(508)Principal payments in connection with leases(11)(35)Net cash provided by (used in) financing activities(439)65,373Effect of exchange rate changes on cash, cash equivalents and restricted cash10831Net increase in cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash at beginning of period147,64085,165	Net cash provided by (used in) investing activities	(24,24	0) 26,121
Net proceeds from exercise of common stock options and employee stock purchases       —       1,054         Repurchase of shares to satisfy employee tax withholding obligations       (428)       (508)         Principal payments in connection with leases       (11)       (35)         Net cash provided by (used in) financing activities       (439)       65,373         Effect of exchange rate changes on cash, cash equivalents and restricted cash       108       31         Net increase in cash, cash equivalents and restricted cash       36,232       138,637         Cash, cash equivalents and restricted cash at beginning of period       147,640       85,165	Financing activities:		
Repurchase of shares to satisfy employee tax withholding obligations(428)(508)Principal payments in connection with leases(11)(35)Net cash provided by (used in) financing activities(439)65,373Effect of exchange rate changes on cash, cash equivalents and restricted cash10831Net increase in cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash at beginning of period147,64085,165	Net proceeds from debt financing	-	- 64,862
Principal payments in connection with leases(11)(35)Net cash provided by (used in) financing activities(439)65,373Effect of exchange rate changes on cash, cash equivalents and restricted cash10831Net increase in cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash at beginning of period147,64085,165	Net proceeds from exercise of common stock options and employee stock purchases	-	— 1,054
Net cash provided by (used in) financing activities(439)65,373Effect of exchange rate changes on cash, cash equivalents and restricted cash10831Net increase in cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash at beginning of period147,64085,165	Repurchase of shares to satisfy employee tax withholding obligations	(42	28) (508)
Effect of exchange rate changes on cash, cash equivalents and restricted cash10831Net increase in cash, cash equivalents and restricted cash36,232138,637Cash, cash equivalents and restricted cash at beginning of period147,64085,165	Principal payments in connection with leases	(*	(35)
Net increase in cash, cash equivalents and restricted cash       36,232       138,637         Cash, cash equivalents and restricted cash at beginning of period       147,640       85,165	Net cash provided by (used in) financing activities	(43	(9) 65,373
Cash, cash equivalents and restricted cash at beginning of period 85,165		10	)8 31
	Net increase in cash, cash equivalents and restricted cash	36,23	32 138,637
Cash, cash equivalents and restricted cash at end of period \$ 183.872 \$ 223.802	Cash, cash equivalents and restricted cash at beginning of period	147,64	10 85,165
	Cash, cash equivalents and restricted cash at end of period	\$ 183.87	2 \$ 223,802

### EHEALTH, INC. SEGMENT INFORMATION (in thousands, unaudited)

We evaluate our business performance and manage our operations as two distinct reporting segments: Medicare and Individual, Family and Small Business. This identification of reportable segments is consistent with how the segments report to and are managed by our chief executive officer, who is our chief operating decision maker. The Medicare segment consists primarily of amounts earned from our sale of Medicare-related health insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans (collectively, the "Medicare Plans"), fees for the performance of administrative services and to a lesser extent, amounts from our sale of ancillary products sold to our Medicare-eligible customers, including but not limited to, dental and vision plans, as well as amounts we are paid in connection with our advertising program for marketing and other services. The Individual, Family and Small Business segment consists primarily of amounts earned from our sale of individual, family and small business health insurance plans, including both qualified and non-qualified plans, and ancillary products sold to our non-Medicare-eligible customers, including but not limited to, dental, vision, and short-term insurance. To a lesser extent, the Individual, Family and Small Business segment consists of amounts earned from our online sponsorship program that allows carriers to purchase advertising space in specific markets in a sponsorship area on our website, our licensing to third parties for the use of our health insurance elam second and our delivery and sale to third parties of individual and family health insurance plan leads generated by our econderece platforms and our marketing activities.

Marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect marketing and advertising, customer care and enrollment and technology and content operating expenses are allocated to each segment based on usage. Corporate consists of other indirect general and administrative operating expenses, excluding stock-based compensation expense, depreciation and amortization, which are managed in a corporate shared services environment and, since they are not the responsibility of segment operating management, are not allocated to the reportable segments and are instead reported within Corporate.

The performance of each reportable segment is evaluated based on several factors, including revenue and segment profit (loss), which is calculated as total revenue for the applicable segment less direct and indirect allocated marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses, excluding stock-based compensation expense, depreciation and amortization and impairment, restructuring and other charges. Senior management uses segment profit (loss) to evaluate segment performance because they believe this measure is indicative of performance trends and the overall earnings potential of each segment.

		Three Months Ended March 31,				
	—	2023		2022	% Change	
Revenue					-	
Medicare	\$	61,834	\$	95,067	(35)%	
Individual, Family and Small Business		11,889		10,183	17 %	
Total revenue	\$	73,723	\$	105,250	(30)%	
Segment profit (loss)						
Medicare	\$	(3,373)	\$	(14,817)	77 %	
Individual, Family and Small Business		7,413		5,254	41 %	
Segment profit (loss)		4,040		(9,563)	142 %	
Corporate		(16,695)		(15,265)		
Stock-based compensation expense		(4,994)		(5,285)		
Depreciation and amortization		(5,245)		(4,778)		
Impairment, restructuring and other charges		_		(4,823)		
Other expense, net		(592)		(1,021)		
Loss before income taxes	\$	(23,486)	\$	(40,735)	42 %	

### EHEALTH, INC. COMMISSION REVENUE (in thousands, unaudited)

Our commission revenue results from approval of an application from health insurance carriers, which we define as our customers under Accounting Standards Codification 606 - Revenue from Contracts with Customers ("ASC 606"). Our commission revenue is primarily comprised of commissions from health insurance carriers which is computed using the estimated constrained lifetime values as the "constrained LTVs" of commission payments that we expect to receive. Our commissions include regular payments with respect to administrative services we perform. Our Medicare Supplement plan commissions include certain bonus payments, which are generally based on our attaining predetermined target sales levels or other objectives, as determined by the health insurance carriers.

The following table presents commission revenue by product for the periods indicated:

	Three Months Ended March 31,			_	
	2023		2022	% Change	
Medicare					
Medicare Advantage	\$ 54,121	\$	78,130	(31)%	
Medicare Supplement	4,065		6,120	(34)%	
Medicare Part D	777		1,460	(47)%	
Total Medicare	 58,963		85,710	(31)%	
Individual and Family	4,006		3,126	28 %	
Ancillary	2,422		2,831	(14)%	
Small Business	4,873		3,483	40 %	
Commission Bonus and Other	(2,261)		(1,300)	(74)%	
Total Commission Revenue	\$ 68,003	\$	93,850	(28)%	

The following table presents a summary of commission revenue by segment for the periods indicated:

		lonths Ended arch 31,
	2023	2022
Medicare		
Commission Revenue from Members Approved During the Period	\$ 56,61	7 \$ 84,283
Net Commission Revenue from Members Approved in Prior Periods <sup>(a)</sup>	5	2 51
Total Medicare Segment Commission Revenue	56,66	9 84,334
Individual, Family and Small Business		
Commission Revenue from Members Approved During the Period	6,70	8 6,042
Commission Revenue from Renewals of Small Business Members During the Period	3,11	3 3,037
Net Commission Revenue from Members Approved in Prior Periods <sup>(a)</sup>	1,51	3 437
Total Individual, Family and Small Business Segment Commission Revenue	11,33	4 9,516
Total Commission Revenue	\$ 68,00	3 \$ 93,850

(a) These amounts reflect our revised estimates of cash collections for certain members approved prior to the relevant reporting period that are recognized as adjustments to revenue within the relevant reporting period. The net adjustment revenue includes both increases in revenue for certain prior period cohorts as well as reductions in revenue for certain prior period cohorts. There were no reductions to revenue from members approved in prior periods for the three months ended March 31, 2023 and 2022.

### EHEALTH, INC. COMMISSION REVENUE (in thousands, unaudited)

### Selected Metrics — First Quarter of 2023

		Three Months Ended March 31,			
		2023		2022	% Change
Approved Members <sup>(2)</sup>					
Medicare					
Medicare Advantage		60,451		82,431	(27)%
Medicare Supplement		4,585		6,556	(30)%
Medicare Part D		3,846		6,823	(44)%
Total Medicare		68,882		95,810	(28)%
Individual and Family		10,099		9,801	3 %
Ancillary		16,656		18,970	(12)%
Small Business		1,939		2,514	(23)%
Total Approved Members		97,576		127,095	(23)%
Constrained Lifetime Value of Commissions per Approved Member <sup>(3)</sup>					
Medicare <sup>(a)</sup>					
Medicare Advantage	\$	901	\$	948	(5)%
Medicare Supplement	Ŷ	880	Ψ	927	(5)%
Medicare Part D		202		213	(5)%
Individual and Family		202		210	(0)/0
Non-Qualified Health Plans		400		330	21 %
Qualified Health Plans		387		302	28 %
Ancillary					
Short-term		187		182	3 %
Dental		110		104	6 %
Vision		70		62	13 %
Small Business		233		198	18 %
(a) Constraints for all Medicare products remained the same for the periods presented.					
Expense Metrics per Approved Member <sup>(4)</sup>					
Medicare					
Customer care and enrollment cost per Medicare Advantage ("MA")-equivalent approved member	\$	375	\$	441	(15)%
Variable marketing cost per MA-equivalent approved member	Ŷ	396	Ŷ	545	(27)%
Total acquisition cost per MA-equivalent approved member	\$	771	\$	986	(22)%
Individual and Family Plan ("IFP")	<u> </u>		. <del>-</del>		(,,,
Customer care and enrollment cost per IFP-equivalent approved member	\$	121	\$	88	38 %
Variable marketing cost per IFP-equivalent approved member	Ψ	40	Ψ	49	(18)%
Total acquisition cost per IFP-equivalent approved member	\$	161	\$	137	18 %
total acquisition cost por in requirement approved member	φ	101	Ψ	101	10 /0

9

Note: See accompanying footnotes on page 12.

	As of Ma	As of March 31,			As of March 31,		
	2023	2022	% Change				
Estimated Membership <sup>(5)</sup>			-				
Medicare <sup>(6)</sup>							
Medicare Advantage	577,500	585,824	(1)%				
Medicare Supplement	94,813	100,006	(5)%				
Medicare Part D	212,183	219,801	(3)%				
Total Medicare	884,496	905,631	(2)%				
Individual and Family <sup>(6)</sup>	98,983	104,849	(6)%				
Ancillary <sup>(6)</sup>	206,610	229,284	(10)%				
Small Business <sup>(7)</sup>	47,531	47,876	(1)%				
Total Estimated Membership	1,237,620	1,287,640	(4)%				

### EHEALTH, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (unaudited)

### Reconciliation of GAAP Operating Costs and Expenses to Non-GAAP Operating Costs and Expenses (in thousands)<sup>(1)</sup>:

	Three Months Ended March 31,			
		2023	<i>.</i>	2022
GAAP marketing and advertising expense	\$	32,899	\$	58,454
Stock-based compensation expense		(455)		(313)
Non-GAAP marketing and advertising expense (1)	\$	32,444	\$	58,141
GAAP customer care and enrollment expense	\$	26,957	\$	42,164
Stock-based compensation expense		(605)		(454)
Non-GAAP customer care and enrollment expense (1)	\$	26,352	\$	41,710
GAAP technology and content expense	\$	15,544	\$	19,663
Stock-based compensation expense		(905)		(1,850)
Non-GAAP technology and content expense (1)	\$	14,639	\$	17,813
GAAP general and administrative expense	\$	21,002	\$	19,987
Stock-based compensation expense		(3,029)		(2,668)
Non-GAAP general and administrative expense (1)	\$	17,973	\$	17,319
GAAP operating costs and expenses	\$	96,617	\$	144,964
Stock-based compensation expense		(4,994)		(5,285)
Impairment, restructuring and other charges		_		(4,823)
Non-GAAP operating costs and expenses (1)	\$	91,623	\$	134,856

Note: See accompanying footnotes on page 12.

Reconciliation of GAAP Net Loss Attributable to Common Stockholders to Adjusted EBITDA and Adjusted EBITDA Margin (in thousands)<sup>(1)</sup>:

	Three Months Ended March 31,				
	 2023		2022		
GAAP net loss attributable to common stockholders	\$ (28,048)	\$	(39,960)		
Paid-in-kind dividends for preferred stock	5,101		4,717		
Change in preferred stock redemption value	3,069		2,501		
GAAP net loss	(19,878)		(32,742)		
Stock-based compensation expense	4,994		5,285		
Depreciation and amortization	5,245		4,778		
Impairment, restructuring and other charges	_		4,823		
Other expense, net	592		1,021		
Benefit from income taxes	(3,608)		(7,993)		
Adjusted EBITDA	\$ (12,655)	\$	(24,828)		
Net income margin	 (27)%		(31)%		
Adjusted EBITDA margin	(17)%		(24)%		

Reconciliation of Guidance GAAP Net Loss Attributable to Common Stockholders to Adjusted EBITDA (millions)<sup>(1)</sup>:

	Full Year 2	Full Year 2023 Guidance		
	Low	High		
GAAP net loss attributable to common stockholders	\$ (90.0	) \$ (70.0)		
Impact from preferred stock	35.0	35.0		
GAAP net loss	(55.0	) (35.0)		
Stock-based compensation expense	22.0	20.0		
Depreciation and amortization	22.0	21.0		
Impairment, restructuring and other charges	5.0	3.0		
Other expense, net	7.0	6.0		
Benefit from income taxes	(16.0	) (10.0)		
Adjusted EBITDA	\$ (15.0	) \$ 5.0		

11

Note: See accompanying footnotes on page 12.

### EHEALTH, INC. Footnotes to Preceding Financial Statements and Metrics

### (1) Non-GAAP Financial Information

This press release includes financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). To supplement eHealth's condensed consolidated financial statements presented in accordance with GAAP, eHealth presents investors with non-GAAP financial measures, including non-GAAP operating costs and expenses, adjusted EBITDA and adjusted EBITDA margin.

- Non-GAAP operating costs and expenses are calculated by excluding the effect of expensing stock-based compensation related to stock options, restricted stock awards, performance-based and market-based awards and employee stock purchase plan. Total non-GAAP operating costs and expenses is calculated by excluding the effect of expensing stock-based compensation related to stock options, restricted stock awards, performance-based and market-based awards and employee stock purchase plan and impairment, restructuring and other charges.
- Adjusted EBITDA is calculated by excluding paid-in-kind dividends for preferred stock and change in preferred stock redemption value (together "the impact from preferred stock"), income tax expense (benefit), depreciation and amortization, stock-based compensation expense, impairment, restructuring and other charges, other income (expense), net, and other non-recurring charges from GAAP net income (loss) attributable to common stockholders. Other non-recurring charges to GAAP net income (loss) attributable to common stockholders may include transaction expenses in connection with capital raising transactions (whether debt, equity or equity-linked) and acquisitions, whether or not consummated, purchase price adjustments and the cumulative effect of a change in accounting principles.
- Adjusted EBITDA margin is calculated as adjusted EBITDA divided by revenue.

eHealth believes that the presentation of these non-GAAP financial measures provides important supplemental information to management and investors regarding financial and business trends relating to eHealth's financial condition and results of operations. Management believes that the use of these non-GAAP financial measures provides consistency and comparability with eHealth's past financial reports. Management also believes that the items described above provide an additional measure of eHealth's operating results and facilitates comparisons of eHealth's core operating performance against prior periods and business model objectives. This information is provided to investors in order to facilitate additional analyses of past, present and future operating performance and as a supplemental measure to evaluate eHealth's ongoing operations. eHealth believes that these non-GAAP financial measures are useful to investors in their assessment of eHealth's operating performance.

Non-GAAP operating costs and expenses, Adjusted EBITDA and Adjusted EBITDA margin are not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures used in this press release have limitations in that they do not reflect all of the revenue and costs associated with the operations of eHealth's business and do not reflect income tax as determined in accordance with GAAP. As a result, you should not consider these measures in isolation or as a substitute for analysis of eHealth's results as reported under GAAP. Health expects to continue to incur the stock-based compensation costs and depreciation ad amortization described above, and exclusion of these costs, and their related income tax benefits, from non-GAAP financial measures should not be construed as an inference that these costs are unusual or infrequent. eHealth compensates for these limitations by prominently disclosing GAAP net income (loss), GAAP net income (loss) attributable to common stockholders and GAAP net income (loss) margin and providing investors with reconciliations for melevant periods.

The tables above provide more details on the GAAP financial measures that are most directly comparable to the non-GAAP financial measures described above and the related reconciliations between these financial measures.

- (2) Approved members represent the number of individuals on submitted applications that were approved by the relevant insurance carrier for the identified product during the current period. The applications may be submitted in either the current period or prior periods. Not all approved members ultimately become paying members.
- (3) Constrained lifetime value ("LTV") of commissions per approved member for Medicare, individual and family and ancillary plans represents commissions estimated to be collected over the estimated life of an approved member's plan after applying constraints in accordance with our revenue recognition policy. Constrained LTV of commissions per approved member for small business represents the estimated commissions we expect to collect from the plan over the following twelve months. The estimate is driven by multiple factors, including but not limited to contracted commission rates, carrier mix, estimated average plan duration, the regulatory environment, and cancellations of insurance plans offered by health insurance carriers with which we have a relationship and applied constraints. The constraints are applied to help ensure that commissions estimated to be collected over the estimated life of an approved member's plan are recognized as revenue only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with future commissions receivable from the plan is subsequently resolved. These factors may result in varying values from period to period.
- (4) Expense Metrics per Approved Member: Marketing initiatives are an important component of our strategy to increase revenue and are primarily designed to encourage consumers to complete an application for health insurance. Variable marketing costs represents direct costs incurred in member acquisition from our direct, marketing partners and online advertising channels. Variable marketing costs exclude fixed overhead costs, such as personnel related costs, consulting expenses, facilities and other

### EHEALTH, INC. Footnotes to Preceding Financial Statements and Metrics

operating costs allocated to the marketing and advertising department. In addition, we incur customer care and enrollment expenses in assisting applicants during the enrollment process.

The numerator used to calculate each metric is the portion of the respective operating expenses for marketing and advertising and customer care and enrollment that is directly related to member acquisition for our sale of Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans (collectively, the "Medicare Plans") and for all individual and family plans and short-term health insurance plans (collectively, the "IFP Plans"), respectively. The denominator used to calculate each metric is based on a derived metric that represents the relative value of the new members acquired. For Medicare Plans, we call this derived metric with a Medicare Part D approved members, and for IFP Plans, we call this derived metric with a Medicare Part D approved member being weighted at 25% of a Medicare Advantage member and Medicare Supplement member based on their relative LTVs at the time of our adoption of ASC 606. We calculate the number of MA-equivalent approved members by adding the total number of approved Medicare Part D members during the periods presented. IFP-equivalent approved members is a derived metric with a short-term approved member being weighted at 25% of the total number of approved Medicare Part D members during the periods presented. IFP-equivalent approved members is a derived metric with a short-term approved member being weighted at 33% of the total number of ASC 606. We calculate the number of plane member based on their relative LTVs at the time of our adoption of ASC 606. We calculate the number of plane member based on their relative LTVs at the time of our ASC 606. We calculate the number of plane members and a member sate 33% of the total number of ASC 606. We calculate the number of approved members by adding the total number of approved members during the periods presented. IFP-equivalent approved members approved members approved member being weighted at 33% of the total number of ASC 606. We calculate the number of approved member based on their relative LTVs at the time o

(5) Estimated membership represents the estimated number of members active as of the date indicated based on the number of members for whom we have received or applied a commission payment during the period of estimation.

Health insurance carriers bill and collect insurance premiums paid by our members. The carriers do not report to us the number of members that we have as of a given date. The majority of our members who terminate their policies do so by discontinuing their premium payments to the carrier or notifying the carrier directly and do not inform us of the cancellation. Also, some of our members pay their premiums less frequently than monthly. Given the number of months required to observe non-payment of commissions in order to confirm cancellations, we estimate the number of members who are active on insurance policies as of a specified date.

After we have estimated membership for a period, we may receive information from health insurance carriers that would have impacted the estimate if we had received the information prior to the date of estimation. We may receive commission payments or other information that indicates that a member who was not included in our estimates for a prior period was in fact an active member at that time, or that a member who was not included in our estimates for a prior period was in fact an active member at that time, or that a member who was not included in our estimates for a prior period was in fact an active member at that time, or that commissions owed to us, which would cause us to have underestimated membership. Conversely, carriers may require us to return commission payments paid in a prior period due to policy cancellations for members we previously estimated as being active. We do not update our estimated membership numbers reported in previous periods. Instead, we reflect updated information from insurance carriers, actual trends in our membership estimate for the current period. If we experience a significant variance in historical membership as compared to our initial estimates, while we keep the prior period data consistent with previously reported amounts, we may provide the updated information in other communications or disclosures. As a result of the delay in our receipt of information from insurance carriers, actual trends in our membership are most discernible over periods longer than from one quarter to the next. As a result of the delay we experience in receiving information about our membership retention. Various circumstances could cause the assumptions and estimates that we make in connection with estimating our membership to the inaccurate, which would cause our membership retention. Various circumstances could cause the assumptions and estimates that we make in connection with estimating our membership to the inaccurate.

- (6) To estimate the number of members on Medicare-related, individual and family, and ancillary health insurance plans, we take the respective sum of (i) the number of members for whom we have received or applied a commission payment for a month that may be up to three months prior to the date of estimation (after reducing that number using historical experience for assumed member cancellations over the period being estimated); and (ii) the number of approved members over that period (after reducing that number using historical experience for an assumed number of members who do not accept their approved policy and for estimated member cancellations through the date of the estimate). To the extent we determine through confirmations from a health insurance carrier that a commission payment is delayed or is inaccurate as of the date of estimation, we adjust the estimated membership to also reflect the number of members for whom we expect to receive or to refund a commission payment. Further, to the extent we have received substantially all of the commission payments related to a given month during the period being estimated, we will take the number of members for whom we have received or applied a commission payment and related reporting from the related carriers.
- (7) To estimate the number of members on small business health insurance plans, we use the number of initial members at the time the group was approved, and we update this number for changes in membership if such changes are reported to us by the group or carrier. However, groups generally notify the carrier directly of policy cancellations and increases or decreases in group size without informing us. Health insurance carriers often do not communicate policy cancellation information or group size changes to us. We often are made aware of policy cancellations and group size changes at the time of annual renewal and update our membership statistics accordingly in the period they are reported.



# Safe Harbor Statement

### **Forward-Looking Statements**

This presentation includes forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally relate to future events or our future financial or operating performance. Forward-looking statements in this presentation include, but are not limited to, the following: our estimates regarding the constrained lifetime value of commissions; our estimates regarding costs per approved member; our 2023 operational initiatives; and our 2023 annual guidance for total revenue, GAAP net loss, adjusted EBITDA and operating cash flow. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks include those set forth in our filings with the Securities and Exchange Commission, including our latest Form 10-Q and 10-K. The forward-looking statements in this presentation are based on information available to us as of today, and we disclaim any obligation to update any forward-looking statements, except as required by law.

### Non-GAAP Information

This presentation includes both GAAP and non-GAAP financial measures. The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for results prepared in accordance with GAAP. A reconciliation of the non-GAAP financial measures included in this presentation to the most directly comparable GAAP financial measures is available in the Appendix to this presentation. Management uses both GAAP and non-GAAP information in evaluating and operating its business internally and as such has determined that it is important to provide this information to investors.



2023 Copyright eHealth Insurance.

# Q1 2023 Highlights

Strong first quarter performance reflects positive impact of the ongoing transformation plan

- Improved earnings compared to last year:
  - Q1 2023 net loss of \$19.9 million compared to net loss of \$32.7 million in Q1 2022
  - > Q1 2023 Adjusted EBITDA<sup>(1)</sup> of \$(12.7) million compared to Adjusted EBITDA<sup>(1)</sup> of \$(24.8) million in Q1 2022
- Operating cash flow increased 29% year-over-year from \$47.1 million in Q1 2022 to \$60.8 million in Q1 2023, driven in part by higher earnings and strong renewal cash collections for our Medicare cohorts

 Unit economics continue to improve on a year-over-year basis with total acquisition costs per MA-equivalent<sup>(2)</sup> approved member down 22% compared to Q1 2022:

- > Customer care and enrollment expense per MA-equivalent<sup>(2)</sup> approved member down 15% year-over-year.
- > Variable marketing cost per MA-equivalent<sup>(2)</sup> approved member down 27% year-over-year.
- Q1 2023 telephonic conversion rates continued to improve on year-over-year basis, increasing 21% compared to Q1 2022.
- Reaffirming our FY 2023 guidance ranges.
- (1) Applies on two accurates by exclusing patient multi all materia so preteries took and change in preteries took reampoint wate (agence) the impact only preteries took in more than a took in the preteries took in th
- because of the second s

eHealth

2023 Copyright eHealth Insurance.




# **Enhanced Q1 Medicare Unit Economics**

 The number of MA-equivalent approved members is calculated by adding the total number of approved Medicare Advantage and Medicare Supplement members and 25% of the total number of approved Medicare Part D members during the period presented;

eHealth

2023 Copyright eHealth Insurance.

# Significant Improvement in Q1 Profitability




(1) Adjusted EBITDA is calculated by excluding the inpact from preferred stock, income tax expense (benefit), depreciation and amortization, stock-based compensation expense, impairment, restructuring and other charges, other income (expense), net, and other non-recurring charges from GAAP net income [loss] attributable to common stockholders. Other non-recurring charges to GAAP net income [loss] attributable to common stockholders. Other non-recurring charges to GAAP net income [loss] attributable to common stockholders, whether or not consummated, purchase price adjustments and the cumulative effect of a change in accounting principles.

eHealth

2023 Copyright eHealth Insurance.

# Q1 Medicare Segment Performance




 Segment loss is calculated as total revenue for the applicable segment less direct and indirect allocated marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses, excluding stock-based compensation expense, depreciation and amortization, and impairment, restructuring and other charges.

eHealth

2023 Copyright eHealth Insurance.

# Q1 Individual, Family, and Small Business Segment Performance



 Segment profit is calculated as total revenue for the applicable segment less direct and indirect allocated marketing and advertising, customer care and enrollment, technology and content and general and administrative operating expenses, excluding stock-based compensation expense, depreciation and amortization, and impairment, restructuring and other charges.

eHealth

2023 Copyright eHealth Insurance.

# **Cash Flow & Liquidity Metrics**

Following a strong cash collection quarter in Q1, our trailing-twelve-month operating cash flow of (\$13.2)M represents a year-overyear improvement of more than \$145M. We believe we have ample liquidity to execute on our 2023 plan.





eHealth

2023 Copyright eHealth Insurance.

# Total Cash Collected by Revenue Type

Total Q1 cash collections of \$160.2M declined 15% year-over-year driven by lower commission and non-commission revenue compared to Q1 2022. This was driven by lower first-year commissions collected as a result of our intentional reduction in customer acquisition spend during the AEP, and partially offset by higher Medicare renewal collections.





 We distinguish between commission and non-commission based cash collections using the same methodology we use to distinguish between commission revenue and revenue from non-commission sources, which can be found in our Annual Report on form 10-K filed with the Securities and Exchange Commission on March 1, 2023.

eHealth

2023 Copyright eHealth Insurance.

# FY 2023 Operational Priorities



eHealth

2023 Copyright eHealth Insurance.

# FY 2023 Guidance

# We are reaffirming our previously issued guidance ranges for the fiscal year ending December 31, 2023:

2023 Full Year Guidance	Range (in millions)
Total Revenue	\$420 – \$440
GAAP Net Loss	\$55 – \$35
Adjusted EBITDA <sup>(1)</sup>	\$(15) – \$5
Operating Cash Flow	\$(30) - \$(15)

(1) Adjusted EBITDA is calculated by excluding the impact from preferred stock, income tax expense [benefit], depreciation and amortization, stock-based compensation expense, impairment, restructuring and other charges, other income [expense], net, and other non-recurring charges from GAAP net income [loss] attributable to common stockholders. Other non-recurring charges to GAAP net income [loss] attributable to common stockholders. Other non-recurring charges to GAAP net income [loss] attributable to common stockholders. Other non-recurring charges to GAAP net income [loss] attributable to common stockholders. Other non-commanded, purchase price adjustments and the cumulative effect of a change in accounting principles.

eHealth<sup>®</sup>

2023 Copyright eHealth Insurance

# Appendix eHealth

2023 Copyright eHealth Insurance.

# Net Loss Attributable to Common Stockholders to Adjusted EBITDA Reconciliation

	(In thousands, unaudited) Three Months Ended March 31,			
		2023		2022
GAAP net loss attributable to common stockholders	\$	(28,048)	\$	(39,960)
Paid-in-kind dividends for preferred stock		5,101		4,717
Change in preferred stock redemption value		3,069		2,501
GAAP net loss	-	(19,878)		(32,742)
Stock-based compensation expense		4,994		5,285
Depreciation and amortization		5,245		4,778
Impairment, restructuring and other charges				4,823
Other expense, net		592		1,021
Benefit from income taxes		(3,608)		(7,993)
Adjusted EBITDA	\$	(12,655)	\$	(24,828)

eHealth

2023 Copyright eHealth Insurance

# Reconciliation of Non-GAAP Financial Measures to Guidance

	(in millions, unaudited) Full Year 2023 Guidance			
		Low	1	High
GAAP net loss attributable to common stockholders	\$	(90.0)	\$	(70.0)
Impact from preferred stock		35.0		35.0
GAAP net loss		(55.0)		(35.0)
Stock-based compensation expense		22.0		20.0
Depreciation and amortization		22.0		21.0
Impairment, restructuring and other charges		5.0		3.0
Other expense, net		7.0		6.0
Benefit from income taxes		(16.0)		(10.0)
Adjusted EBITDA	\$	(15.0)	\$	5.0

eHealth<sup>®</sup>

2023 Copyright eHealth Insurance